Location of Repository

Measurement of physiological variables by dynamic Gd-DTPA enhanced MRI

By Aleksandra Radjenovic

Abstract

Abnormal angiogenesis is characterised by the alteration of physiological variables such as capillary permeability and fractional volume of the extravascular extracellular space. The aim of the work presented in this thesis was to investigate the feasibility of non-invasive measurement of these physiological variables through quantitative analysis of dynamic Gd-DTPA enhanced MRI (DEMRI) acquired using standard imaging hardware within a clinical setting.\ud \ud A method for quantitative analysis of DEMRI (QDEMRI) was developed and implemented on a standard personal computer platform using a set of programs written in the C\ud programming language. The method includes pharmacokinetic modelling of Gd-DTPA kinetics based on the modification of existing approaches and moving-window algorithms\ud for the measurement of black-box quantifiers of DEMRI.\ud \ud The measurements were performed in two angiogenesis dependent diseases: breast cancer and rheumatoid arthritis (RA). In a study involving QDEMRI analysis of 59 primary invasive breast carcinomas, a significant relationship between capillary permeability-related QDEMRI variables and tumour grade was found. In a randomised controlled study of early RA in metacarpophalangeal joints, a significant reduction in the QDEMRI variable which reflects fractional volume of the extravascular extracellular space was found three months after the start of therapy in 20 patients treated with methotrexate and intra-articular\ud methylprednisolone injections, whereas it remained constant in a control group of 17 patients who were treated with slow-acting methotrexate only. A significant reduction in the permeability-related QDEMRI variable was detected in 17 patients treated with leflunomide four months after the start of treatment whilst it remained unchanged in 17 patients treated with methotrexate in a randomised controlled study of established RA of the knee joint.\ud \ud The results obtained in this work indicate that the proposed QDEMRI method can be used in its present form to monitor treatment-induced changes in angiogenesis dependent\ud diseases. Further work is needed to render these measurements fully independent of DEMRI acquisition settings and allow the evaluation of individual lesions

Publisher: School of Medicine (Leeds)
Year: 2003
OAI identifier: oai:etheses.whiterose.ac.uk:356

Suggested articles

Preview

Citations

  1. A comparative study by morpbometry of the microvasculature in normal and rheumatoid ynovium.
  2. A comparison of the effzcary and safety of kflunomide and methotrexate for the treatment of rheumatoid arthritis.
  3. A review of 1H nuclear magnetic resonance relaxation in pathology: Are Ti and T2 diagnostic? doi
  4. A review of normal tissue bydmgen NMR relaxation timet and relaxation mechanisms from 1-100 MHO Dependence on tissue type, NMR frequency, temperature, species, excision, and age. doi
  5. A trial of etanercept, a recombinant tumor necrosis factor receptor : Fe fusion protein, in patients with rheumatoid arthritis receiving methottexate. doi
  6. (1992). Accurate and precise measurement of blood-retinal barrier breakdown using dynamic Gd-DTPA
  7. Adhesion molecule expression in human rynovial daue.
  8. Albumin labeled with Gd-DTPA - An Intravascular contrast-enhancing agent for magnetic resonance blood pool imaging -Preparation and characterisation. doi
  9. Angiogenecis in wound healing.
  10. Angiogenenr of uterine cervical carcinoma: Characterization by pharmacokinetic magnetic resonance parameters and histological microve uel density with correlation to lymphatic involvement.
  11. Angiogenerir mediated by soluble forms of E-selectin and vascular cell-adhesion molecule-1. doi
  12. Angiogeneris in cancer, vascular, rheumatoid and other disease. doi
  13. Angiogenes s and rheumatoid arthritis - Pathogenic and therapeutic implications. doi
  14. Angiogenesir in the female reproductive rystem.
  15. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast ksions. doi
  16. (1997). Angiogenesis in irchemir heart disease. Nature Medicine, doi
  17. Angiogenesis in pannus formation. Agents and Actions, doi
  18. (1998). Angiogenesis in rheumatoid arthritis: Implications for future therapeutic strategies. Springer Seminars in Immunopathology, doi
  19. Angiogenesis in rheumatoid arthritis: Pathogenic and clinical significance. doi
  20. Angiogenicgrowth factors in neural embryogenesit and neoplasia.
  21. Application of a mixed imaging sequence forMR-imaging characterisation of human breast disease.
  22. Approximation of arterial input curve data in MRI estimation of cerebral blood-tumor-barrier leakage: Comparison between Gd- DTPA and Tc-99m-DTPA input curves. doi
  23. (1997). Arthritic temporomandibularjoint. Correlation of macmmolecular contrast-enhanced MR imaging parameters and bistopathologic6ndings. Radiology,
  24. Assessment o fa rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to bistopathology. Magnetic Resonance in doi
  25. Basic physics of MR contrast agents and maximisation of image contrast. doi
  26. Benign and malignant breast lesions - Differrntiation with echo planarMR imaging.
  27. Biodistribution and toxicity oJMR imaging contrast media. doi
  28. (2000). Blood Perfusion and Micmenvironment of Human Tumors: Implications for Clinical Radiooncology. doi
  29. Breast disease: Dynamic spiral MR imaging.
  30. Breast lesions: Correlation of contrast medium enbancementpatterns on MR imager with birtopathologicfrndings and tumorangiogenesis.
  31. Breast neoplasms. T2* suaeptibility-contrast, first parr perfusion MR imaging.
  32. (2000). by Houghton Mijh'n Company. Reproduced by permi lion from The American Heritage Dictionary of the English Language, Fourth Edition.
  33. Changes in articular ynovial lining volume measured by magnetic resonance in a randomized, double-blind, controlled trial of infra-articular samarium-153 particulate bydroxyapatite for chronic knee ynovitis. doi
  34. Changes in ynovial membrane and joint effusion volumes after intraarticular methy prednisolone. Quantitative assessment of inflammatory and destructive changes in arthritis by MRI.
  35. Clinical application of antiangiogenic therapy: Microve sel density, what it does and doesn't tell us. doi
  36. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. doi
  37. Comparative assessment of leflunomide and methotnxate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. doi
  38. (1983). Compartmental Models and Their Application. doi
  39. Consequences of delayed therapy with second line agents in rheumatoid arthritic. A 3yearfolloly up on the hydroxychloroguine in early, rheumatoid arthritis (HERA) study.
  40. Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. doi
  41. Contrast-enhanced MRl of the breast Accurag, value, controversies, solutions doi
  42. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media. doi
  43. Decreased angiogenerir and arthritic disease in rabbits treated with an alpha v beta 3 antagonist.
  44. Diabetic-rotinopathy - Pathogenesis and the role of retina-derived growth factor in angiogeneris. doi
  45. Dynamic 3D MR mammography: Is there a benefit of sophisticated evaluation for enhancement curves for clinical routine? doi
  46. Dynamic breast MR imaging: Are signal intensity time course data useful for dferential diagnorir of enhancing lesions?
  47. Dynamic contract-enhanced magnetic resonance imaging of the breast combined with pbarmacakinetic anaysit ofgadolinium- DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma. doi
  48. Dynamic echo planar imaging of the breast. Experience in diagnosing breast carcinoma and correlation with tumor angiogenesis.
  49. Dynamic image interpretation ofMRI of the breast. doi
  50. Dynamic magnetic resonance imaging for the evaluation of rynovitis in patients with rheumatoid arthritis Arthritis and Rheumatism, doi
  51. Dynamic MR imaging of invasive breast cancer. Correlation with tumourgrade and other birtologicalfactorr.
  52. Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours. doi
  53. Early rheumatoid disease. II. Patterns ofjoint involvement.
  54. (2003). Early stage rheumatoid arthritic: Prospective study of the eectivenesr of MR imaging for diagnosis. doi
  55. Effects ofpulse methyprednirolone on inflammatory mediators in peripheral blood, rynovial Fluid, and ynovial membrane in rheumatoid arthritis.
  56. (1997). Elevated levels of the angiogenic glokines basic fibroblastgmwth factor and vascular endothelialgrowth factor in sera of cancerpatients.
  57. Elucidation of the relationsh p between tynovitis and bone damage -A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. doi
  58. Embryonic angiogenesi. r factors. doi
  59. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. doi
  60. et a1, Quantitativegadopentetate-enhanced MRI of breast tumors: Testing of di, fferent analytic methods.
  61. et al, In vivo quantification of the unidirectional influx constant for GdDTPA diffusion across the myocardial capillaries with MR imaging. doi
  62. et al, Quantification of rheumatoid ynovitis by magnetic resonance imaging.
  63. et at, Assessment of tumor vasculaiiZation: Immunohirtochemical and non-invasive methods.
  64. (2002). Etanercept versus methotrexate in patients with early, rheumatoid arthritis - Twoyear radiographic and clinical outcomes. Arthritis and Rheumatism, doi
  65. Expression of basic fibroblastgrowth factor in ynovial tissue from patients with rheumatoid arthritis and degenerative joint disease.
  66. Fingerjoint ynovitis in rheumatoid artbritir. "Quantitative assessment by magnetic resonance imaging. doi
  67. FLASH imaging - Rapid NMR imaging using lowflip-angle pulses. doi
  68. Focally regulated endothelial proliferation and cell death in human rynovium.
  69. Fundamental concepts. Magnetic Resonance in doi
  70. Gadolinium-DTPA in rheumatoid arthritis and related diseases - First results with dynamic magnetic resonance imaging. doi
  71. Gd-enhanced dynamic magnetic resonance imaging of breartmasser. Topics doi
  72. Image formation by induced local interactions. Examples of employing nuclear magnetic resonance. doi
  73. InfTiximab and methotrexate in the treatment of rheumatoid artbriti r New England
  74. Inhibition of angiogenesir and murine bemangiomagrowtb by batimastat, a ryntbetic inhibitor of matrix metalloproteinaser.
  75. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. doi
  76. Inhibition of human endotbelial cellpmliferation bygold compounds.
  77. (1999). Instrumentation, in Magnetic Resonance Imaging, doi
  78. Integrin afpha V beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. doi
  79. Intl ximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial doi
  80. Intra-articularprimatised anti-CD4: Efca y in resistant rheumatoid knees. A study of combined artbroscopy, magnetic resonance imaging, and histology.
  81. Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours. doi
  82. Invasive breast carcinoma - Analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S phase percentage. doi
  83. Leflunomide suppresses TNFinduced cellular responses. effects on NF-kappa B, activator protein-1, e Jun N-terminal protein kinase, and apoptorir doi
  84. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at jour months after symptom onset. doi
  85. Magnetic resonance imaging-determined ynovial membrane and joint effusion volumes in rheumatoid arthritis and o rteoarthritit -Companion with the macroscopic and microscopic appearance of the ynovium. doi
  86. (1999). Magnetic Resonance Imaging: Physical Principles and Sequence Design.
  87. (1999). Magnetic Resonance Imaging. 3rd ed.
  88. Mammary fibroblasts may influence breast-tumor angiogenesis via hypoxiainduced vascular endothelialgrowth factor up-regulation and protein expression.
  89. Mapping abnormal ynovial vascularpermeability in temporomandibularjoint arthritis in the rabbit using MRI.
  90. Measurement of blood brain barrierpermeability using dynamic Gd-DTPA scanning -A comparison of methods. Magnetic Resonance doi
  91. Measurement of capillary permeability from the Gd enhancement curve -A comparison of bolus and constant infusion injection methods. doi
  92. Measurement of gnovial lining volume by magnetic resonance imaging of the knee in chronic ynovitis.
  93. Measurement of the arterial concentration of Gd-D7PA using MRI: " A step toward quantitative perfusion imaging. doi
  94. Measurement of the blood-brain-barrierpermeability and leakage space using dynamic MR imaging . doi
  95. Mechanisms of action of antimalarials in inflammation - Induction of apoptosis in human endothelial cells.
  96. Microve sel density in invasive breast cancer assessed by dynamic GdDTPA enhanced MRI.
  97. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. doi
  98. Molecular therapeutics - Methotrexate and its mechanism of action. doi
  99. MR cbaracteiiZation of suspicious breast lesions with agadolinium-enhanced turboFLASH subtraction technique.
  100. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with bistopatbologic correlation.
  101. MR imaging of the arthritic rabbit knee joint using albumin (GdDTPA)(30) with correlation to bistopathology. doi
  102. MR imaging of the breast - Fast imaging sequences with and s thout Gd-DTPA - Preliminary observations.
  103. MR imaging of the breast using gadolinium-DTPA. doi
  104. MR imaging of the breast with Gd-DTPA: Use and limitations.
  105. MR imaging of the breast with rotating delivery of excitation off resonance -Clinical experience with pathological correlation.
  106. MR imaging of tumor microcirculation: Promise for the new millenium. doi
  107. MR micmcirculation assessment in cervical cancer. Comlations with bistomorphological tumor markers and clinical outcome.
  108. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to bistopatbology. doi
  109. MRI of breast tumors. doi
  110. MRI of the knee in rheumatoid arthritis - Gd-DTPA perfusion dynamics. doi
  111. Multi-planar image formation using NMR spin echoes. doi
  112. Multicompartment analysis ofgadolinium chelate kinetics: Blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. doi
  113. Myocardial perfusion modeling using MRI.
  114. Ni-DTPA doped agarosegel -A phantom material for Gd-DTPA enhancement mearnrrments. doi
  115. Non palpable breast tumors - Diagnosis with contrast-enhanced subtraction dynamic MR imaging.
  116. Non-invasive methods of assessing angiogenesir and their value in predicting response to treatment in colorectal cancer.
  117. Nuclear induction. doi
  118. Nuclear magnetic resonance (NMR) tomographic imaging forpopliteal rysts in rheumatoid arthritis.
  119. (1982). Nuclear Magnetic Resonance and its Applications to Living Systems. doi
  120. Nuclear magnetic resonance studies of cancer. I/I. Relationship among spinlattice relaxation times, growth rate, and water content ofMorris be├čatomar.
  121. Nuclear magneticresonance investigations of p. human neoplartic and abnormal aonneoplartic tissues.
  122. Pannus and pannoryter - Alternative models ofjoint destruction in rheumatoid arthritis.
  123. Paramagnetic metal complexes as waterproton relaxation agents forNMR imaging - Theory and design. doi
  124. Pathophysiologic basis of contrast enhancement in breast tumors.
  125. Patterns and emerging mechanisms of the angiogenic switch during tumorigeneris doi
  126. Peripheral enhancement and spatial contrast uptake betemgeneity of primary breast tumours: Quantitative assessment with dynamic MRI. doi
  127. Pharmaco kinetic mapping of the breast -A new method for dynamic MR mammography. doi
  128. Pharmacokinetic anafylu of Gd-DT PA enhancement in dynamic threedimensionalMRl of breast lesions.
  129. Pharmacokineticr of Gd-DTPA dimeglumine after intravenous injection into healthy volunteers.
  130. (1993). Pharmacokinetics for the Pharmaceutical Scientist.
  131. (1999). Practical Statistics forMedical Research.
  132. (1999). Principles of NuclearMagentism.
  133. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. doi
  134. Proton relaxation times in paramagnetic solutions. doi
  135. Quantification of inflammation in the wrist with gadolinium-enhancedMR imaging and PET with 2-[F-18] fluoro-2-deoxy-Dglucose.
  136. Quantification of rynovitis by MRI. - Correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and macroscopic signs of . ynovialinflammation. doi
  137. Quantitation of blood brain barrier defect by magnetic resonance imaging andgado/inium-DTPA inpatients with multiple sclerosis and brain tumors. doi
  138. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model Magnetic Resonance doi
  139. Quantitative analysis of multis/ice Gd-Dtpa enhanced dynamic MR images using an automated simplex minimization procedure. Magnetic Resonance doi
  140. Quantitative Analysis of Multis/ice Gd-Dtpa Enhanced Dynamic MrImages Using an
  141. Quantitative assessment of the rheumatoid ynovial microvascular bed by gadolinium-DTPA enhanced magnetic resonance imaging. doi
  142. Quantitative assessment of the ynovial membrane in the rheumatoid wist: An easily obtained MRI score reflects the ynovial volume. doi
  143. Quantitative assessment of ynovial inflammation by dynamic gadoliniumenhanced magnetic resonance imaging. A study of the effect of infra-articular methylprednisolone on the rate of early ynovial enhancement.
  144. Quantitative magnetic resonance imaging of the knee: A method of measuring response to intra-articulartreatments. doi
  145. Radiographic thin-section image of the human wrist by nuclear magnetic resonance. doi
  146. Random numbergenerators - Good ones are hard to find. doi
  147. RARE imaging -a fast imaging method for clinica/MR. doi
  148. Recurrent rectal cancer - Diagnosis with dynamic MR-imaging.
  149. (1996). Reduction in long-term disability inpatients with rheumatoid arthritis by diseasemod├čing antirheumatic drug-based treatment strategies. Arthritis and Rheumatism, doi
  150. Regulators of angiogenesis. doi
  151. Relaxation processes in a rystem of two spins. doi
  152. Repeated therapy with monoclonal antibody to tumor necrosis factor (CA 2) in patients with rheumatoid arthritis. doi
  153. Requirement of Vascular Integrin Alpha(V)Beta(3) forAngiogenesis. doi
  154. Resonance absorption by nuclear magnetic moments in solid The Physical Review, 1946.69: doi
  155. Reviere: Angiogenesir. Implicationsforrheumatoid arthritis.
  156. (1990). Rheumatoid arthritis - Evaluation of hypervarcular and fibrous pannus with dynamic MR imaging enhanced with Gd-DTPA. Radiology,
  157. (1987). Rheumatoid arthritis - MR imaging manifestations. Radiology,
  158. Rheumatoid arthritis of the knee - Value ofgadopentetate dimeglumine enhanced MR imaging. doi
  159. (1998). Rheumatoid arthritis: classification and epidemiology, doi
  160. Rheumatoid knee - Role ofgadopentetate-enhanced MR imaging.
  161. Robitaill e, Biological effects and health implications in magnetic resonance imaging. doi
  162. Role of metacarpopbalangeal joint anatomic factors in the distribution of ynovitis and bone erosion in early, rheumatoid arthritis.
  163. Safety and effectiveness of leflunomide in the treatment ofpatients with lled, phase-II study. Arthritis active rheumatoid arthritis - Results of a randomized, placebo-contro and Rheumatism,
  164. Spin war NMR imaging and applications to human whole-body imaging. doi
  165. Suspect breast lesions - Findings at dynamic gadolinium enhanced MR imaging correlated with mammographic and pathological features.
  166. Suspicious breast lesions - MR imaging with radiologicpatbological correlation.
  167. Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-7NF alpha antibody in rheumatoid arthritis. doi
  168. Temporal sampling requirements for the tracer kinetics modeling of breast disease. doi
  169. (1987). The American Rheumatism Association doi
  170. The biology of vascular endothelial growth factor. doi
  171. The effectiveness of early treatment with "second-line" antirheumatic drugs -A randomized, contmlled trial doi
  172. The Nottingham prognostic index in primary breast cancer. doi
  173. The relationship between ynovitis and bone changes in early untreated rheumatoid arthritis -A controlled magnetic resonance imaging study. doi
  174. (2000). The role of microcirculation in the treatment of malignant tumours: facts and fction, in Blood Perfusion and Microenvimnment of Human Tumors. Implications for Clinical doi
  175. The theory and applications of the exchange of inertgas at the lungs and tissues.
  176. Time-de endent vascular regression and permeability changer in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. doi
  177. (1985). Tissue distribution and magnetic resonance spin-lattice relaxation effects of Gadolinium-DTPA.
  178. Treatment of active rheumatoid arthritis with leunomide compared with placebo and methotrexate. doi
  179. Treatment with leflunomide slows radiographicprogresrion of rheumatoid arthritis - Results from three randomized controlled trials of kflunomide in patients with active rheumatoid arthritis. doi
  180. Tumor angiogeneris and metastasis - Correlation in invasive brrast carcinoma.
  181. Tumor angiogenesis -A new significant and independent prognostic indicator in early stage breast carcinoma. doi
  182. Tumor angiogenesit correlates with metastasis in invasive prostate carcinoma.
  183. Tumor cells secrete a vascularpermeability factor that promotes accumulation of asciter fluid. doi
  184. Tumor detection by nuclear magnetic resonance. doi
  185. Tumor vascularity: A histological measure of angiogenesis and hypoxia.
  186. Tumor-derived expression of vascular endotbelialgrowth factor is a critical factor in tumor expansion and vascularfunction.
  187. (2001). Two year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis and Rheumatism, doi
  188. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weightedMRI.
  189. Uterine cerv ca! carcinoma: Comparison of standard and pharmacokinetic analysis of time-intensity carver for assessment of tumor angiogene ri r and patient turvivaL
  190. Vascular and extravascular spaces in two transplantable tumors of the rat. doi
  191. (1979). Vascular and extravscular spaces in tumors: tumor vascularpermeability, in Tumor Blood Circulation. Angiogenesis, VascularMorpbology and Blood Flow of Experimental and
  192. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. doi
  193. Vascular endotbelialgrowth factor as a marker of tumor endothelium.
  194. Vascular endothelial growth factor (VEGF) in human breast cancer. Correlation with disease free su, vival. doi
  195. Vascular endothelial growth factor in ocular fluid ofpatients with diabetic retinopathy and other retinal disorders. doi
  196. (1975). Vascular structures in brain tumors. Human Pathology,
  197. Vascularpermeabi/ity in a human tumor xenograft - Molecular-site dependence and cutoff size.
  198. (1993). Vascularpermeabilily factor (VPF, VEGF) in tumor biology. Cancer and Metastasis Reviews, doi
  199. Vascularpermeability and microcirculation ofgliomas and mammary carcinomas plantedin rat and mouse cranial windows.
  200. Vasculature of neural neoplasms.
  201. Water diffusion and exchange as they influence contrast enhancement. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.